An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer

International Immunopharmacology

Volumn 24, Issue 2, 2015, Pages 335-345

  Chatterjee, Reshmi ^a   Mitra, Abhisek ^b  

^a ESI Hospital   (India)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; Clinical trials; HBV; HCC; HCV; Therapy

Indexed keywords

ACAMPROSATE; ADEFOVIR; ALPHA FETOPROTEIN; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; BACLOFEN; BIOLOGICAL MARKER; CLEVUDINE; DISULFIRAM; ENTECAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LAMIVUDINE; METFORMIN; MICRORNA; NALTREXONE; PEGINTERFERON ALPHA2A; PENTOXIFYLLINE; PIOGLITAZONE; SORAFENIB; TELBIVUDINE; TENOFOVIR;

ALCOHOL LIVER DISEASE; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; CIRCULATING TUMOR CELL; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; ELASTOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEMBRANE MICROPARTICLE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; ULTRASOUND; VIRUS HEPATITIS; LIVER DISEASES; METABOLISM;

BIOMARKERS; HUMANS; LIVER DISEASES;

EID: 84920733357     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.12.024     Document Type: Review

References (149)

1. G.L. Davis, El-Serag H. Alter MJ, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521 [521 e511-516]
2. S. Urbani, B. Amadei, D. Tola, M. Massari, S. Schivazappa, and G. Missale PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion J Virol 80 2006 11398 11403
3. J. Samal, M. Kandpal, and P. Vivekanandan Molecular mechanisms underlying occult hepatitis B virus infection Clin Microbiol Rev 25 2012 142 163
4. Y. Kondo, M. Ninomiya, E. Kakazu, O. Kimura, and T. Shimosegawa Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection ISRN Gastroenterol 2013 2013 935295
5. J.K. Flynn, G.J. Dore, M. Hellard, B. Yeung, W.D. Rawlinson, and P.A. White Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users J Viral Hepat 18 2011 549 561
6. M. Abel, D. Sene, S. Pol, M. Bourliere, T. Poynard, and F. Charlotte Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection Hepatology 44 2006 1607 1616
7. A. Albecka, S. Belouzard, A. Op de Beeck, V. Descamps, L. Goueslain, and J. Bertrand-Michel Role of low-density lipoprotein receptor in the hepatitis C virus life cycle Hepatology 55 2012 998 1007
8. B. Rehermann Hepatitis C, virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Invest 119 2009 1745 1754
9. S. Li, L.E. Vriend, I.A. Nasser, Y. Popov, N.H. Afdhal, and M.J. Koziel Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis Hepatology 56 2012 2094 2105
10. G.A. Michelotti, M.V. Machado, and A.M. Diehl NAFLD, NASH and liver cancer Nat Rev Gastroenterol Hepatol 10 2013 656 665
11. D.A. Sass, P. Chang, and K.B. Chopra Nonalcoholic fatty liver disease: a clinical review Dig Dis Sci 50 2005 171 180
12. A. Wree, L. Broderick, A. Canbay, H.M. Hoffman, and A.E. Feldstein From NAFLD to NASH to cirrhosis - new insights into disease mechanisms Nat Rev Gastroenterol Hepatol 10 2013 627 636
13. S.K. Erickson Nonalcoholic fatty liver disease J Lipid Res 50 2009 S412 S416 [Suppl.]
14. M Iu, C. Singh, M.A. Ganie, and K. Alsayari NASH: the hepatic injury of metabolic syndrome: a brief update Int J Health Sci (Qassim) 3 2009 265 270
15. H. Tilg, and A.R. Moschen Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 52 2010 1836 1846
16. S. Coulon, V. Legry, F. Heindryckx, C. Van Steenkiste, C. Casteleyn, and K. Olievier Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models Hepatology 57 2013 1793 1805
17. K. Wouters, P.J. van Gorp, V. Bieghs, M.J. Gijbels, H. Duimel, and D. Lutjohann Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis Hepatology 48 2008 474 486
18. M. Vijay-Kumar, J.D. Aitken, F.A. Carvalho, T.C. Cullender, S. Mwangi, and S. Srinivasan Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5 Science 328 2010 228 231
19. G. Musso, R. Gambino, G. Biroli, M. Carello, E. Faga, and G. Pacini Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis Am J Gastroenterol 100 2005 2438 2446
20. J.S. Lee, Z. Zheng, R. Mendez, S.W. Ha, Y. Xie, and K. Zhang Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model Toxicol Lett 211 2012 29 38
21. W.K. Syn, K.M. Agboola, M. Swiderska, G.A. Michelotti, E. Liaskou, and H. Pang NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease Gut 61 2012 1323 1329
22. H. Paula, S.K. Asrani, N.C. Boetticher, R. Pedersen, V.H. Shah, and W.R. Kim Alcoholic liver disease-related mortality in the United States: 1980-2003 Am J Gastroenterol 105 2010 1782 1787
23. Y.W. Huang, YSS, and J.H. Kao Pathogenesis and management of alcoholic liver cirrhosis: a review Hepat Med Evid Res 2011 2010 1 11
24. E.S. Orman, G. Odena, and R. Bataller Alcoholic liver disease: pathogenesis, management, and novel targets for therapy J Gastroenterol Hepatol 28 Suppl. 1 2013 77 84
25. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2001 533 543
26. A. Mitra, A. Satelli, X. Xia, J. Cutrera, M. Lopa, and S. Li Cell-surface Vimentin (csVim): a mislocalized protein for isolating csVimentin CD133 novel stem-like hepatocellular carcinoma cells expressing EMT markers Int J Cancer 2014
27. R. Dhanasekaran, A. Limaye, and R. Cabrera Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics Hepat Med 4 2012 19 37
28. A. Arzumanyan, H.M. Reis, and M.A. Feitelson Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma Nat Rev Cancer 13 2013 123 135
29. R.N. Aravalli, C.J. Steer, and E.N. Cressman Molecular mechanisms of hepatocellular carcinoma Hepatology 48 2008 2047 2063
30. A. Satelli, A. Mitra, J.J. Cutrera, M. Devarie, X. Xia, and D.R. Ingram Universal marker and detection tool for human sarcoma circulating tumor cells Cancer Res 74 2014 1645 1650
31. A. Mitra, A. Satelli, J. Yan, X. Xueqing, M. Gagea, and C.A. Hunter IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice Hepatology 60 2014 2027 2039
32. A. Mitra, L. Mishra, and S. Li Technologies for deriving primary tumor cells for use in personalized cancer therapy Trends Biotechnol 31 2013 347 354
33. A. Mitra, J.A. Ross, G. Rodriguez, Z.S. Nagy, H.L. Wilson, and R.A. Kirken Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies J Biol Chem 287 2012 16596 16608
34. Z.S. Nagy, M.J. LeBaron, J.A. Ross, A. Mitra, H. Rui, and R.A. Kirken STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells Mol Cancer 8 2009 67
35. L.N. Qi, T. Bai, Z.S. Chen, F.X. Wu, Y.Y. Chen, and B. De Xiang The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure Liver Int 2014
36. A. Villanueva, D.Y. Chiang, P. Newell, J. Peix, S. Thung, and C. Alsinet Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983 [1983 e1971-1911]
37. J.S. Chen, Q. Wang, X.H. Fu, X.H. Huang, X.L. Chen, and L.Q. Cao Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9 Hepatol Res 39 2009 177 186
38. S.M. Morris, J.Y. Baek, A. Koszarek, S. Kanngurn, S.E. Knoblaugh, and W.M. Grady Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss Hepatology 55 2012 121 131
39. D. Javelaud, and A. Mauviel Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis Oncogene 24 2005 5742 5750
40. Y.E. Zhang Non-Smad pathways in TGF-beta signaling Cell Res 19 2009 128 139
41. J. Fung, M.F. Yuen, J.C. Yuen, D.K. Wong, and C.L. Lai Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study Aliment Pharmacol Ther 26 2007 377 382
42. H.J. Yuan, M.F. Yuen, D. Ka-Ho Wong, E. Sablon, and C.L. Lai The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B J Viral Hepat 12 2005 373 379
43. M.J. Sonneveld, and H.L. Janssen Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int 31 Suppl. 1 2011 78 84
44. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
45. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
46. C. Sarrazin, C. Hezode, S. Zeuzem, and J.M. Pawlotsky Antiviral strategies in hepatitis C virus infection J Hepatol 56 Suppl. 1 2012 S88 S100
47. E. Lawitz, F.F. Poordad, P.S. Pang, R.H. Hyland, X. Ding, and H. Mo Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 383 2014 515 523
48. M.M. Manos, V.A. Shvachko, R.C. Murphy, J.M. Arduino, and N.J. Shire Distribution of hepatitis C virus genotypes in a diverse US integrated health care population J Med Virol 84 2012 1744 1750
49. S.A. Brethauer, B. Chand, and P.R. Schauer Risks and benefits of bariatric surgery: current evidence Cleve Clin J Med 73 2006 993 1007
50. R. Lomonaco, N.E. Sunny, F. Bril, and K. Cusi Nonalcoholic fatty liver disease: current issues and novel treatment approaches Drugs 73 2013 1 14
51. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, and N.M. Bass Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
52. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
53. A. Vitale, E. Gringeri, M. Valmasoni, F. D'Amico, A. Carraro, and A. Pauletto Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience Transplant Proc 39 2007 1892 1894
54. P. Rougier, E. Mitry, J.C. Barbare, and J. Taieb Hepatocellular carcinoma (HCC): an update Semin Oncol 34 2007 S12 S20
55. J.P. Duffy, J.R. Hiatt, and R.W. Busuttil Surgical resection of hepatocellular carcinoma Cancer J 14 2008 100 110
56. B. Gangadharan, R. Antrobus, R.A. Dwek, and N. Zitzmann Novel serum biomarker candidates for liver fibrosis in hepatitis C patients Clin Chem 53 2007 1792 1799
57. L.A. Adams Biomarkers of liver fibrosis J Gastroenterol Hepatol 26 2011 802 809
58. J. Ozer, M. Ratner, M. Shaw, W. Bailey, and S. Schomaker The current state of serum biomarkers of hepatotoxicity Toxicology 245 2008 194 205
59. J. Guechot, A. Laudat, A. Loria, L. Serfaty, R. Poupon, and J. Giboudeau Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis Clin Chem 42 1996 558 563
60. H. Parsian, A. Rahimipour, M. Nouri, M.H. Somi, D. Qujeq, and M.K. Fard Serum hyaluronic acid and laminin as biomarkers in liver fibrosis J Gastrointestin Liver Dis 19 2010 169 174
61. Y. Saitou, K. Shiraki, Y. Yamanaka, Y. Yamaguchi, T. Kawakita, and N. Yamamoto Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease World J Gastroenterol 11 2005 476 481
62. S. Tanwar, P.M. Trembling, I.N. Guha, J. Parkes, P. Kaye, and A.D. Burt Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease Hepatology 57 2013 103 111
63. Y. Murawaki, M. Koda, K. Okamoto, K. Mimura, and H. Kawasaki Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C J Gastroenterol Hepatol 16 2001 777 781
64. R. Flisiak, P. Maxwell, D. Prokopowicz, P.M. Timms, and A. Panasiuk Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1 - possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis Hepatogastroenterology 49 2002 1369 1372
65. G. Tarantino, C. Finelli, A. Colao, D. Capone, M. Tarantino, and E. Grimaldi Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med 10 2012 50
66. G. Tarantino, A. Colao, D. Capone, P. Conca, M. Tarantino, and E. Grimaldi Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease J Biol Regul Homeost Agents 25 2011 47 56
67. G. Tarantino, F. Scopacasa, A. Colao, D. Capone, M. Tarantino, and E. Grimaldi Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease World J Gastroenterol 17 2011 5280 5288
68. K. Peterson Biomarkers for alcohol use and abuse Alcohol Res Health 28 2005 30 37
69. P.L. Hoffman, J. Glanz, and B. Tabakoff Platelet adenylyl cyclase activity as a state or trait marker in alcohol dependence: results of the WHO/ISBRA study on state and trait markers of alcohol use and dependence Alcohol Clin Exp Res 26 2002 1078 1087
70. J.H. Krystal, J. Staley, G. Mason, I.L. Petrakis, J. Kaufman, and R.A. Harris Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment Arch Gen Psychiatry 63 2006 957 968
71. M.R. Munafo, E.C. Johnstone, K.I. Welsh, and R.T. Walton Association between the DRD2 gene Taq1A (C32806T) polymorphism and alcohol consumption in social drinkers Pharmacogenomics J 5 2005 96 101
72. J. Zalewska-Kaszubska, and E. Czarnecka Deficit in beta-endorphin peptide and tendency to alcohol abuse Peptides 26 2005 701 705
73. G. Oroszi, and D. Goldman Alcoholism: genes and mechanisms Pharmacogenomics 5 2004 1037 1048
74. F.M. Wurst, G.E. Skipper, and W. Weinmann Ethyl glucuronide - the direct ethanol metabolite on the threshold from science to routine use Addiction 98 Suppl. 2 2003 51 61
75. A. Helander, and O. Beck Mass spectrometric identification of ethyl sulfate as an ethanol metabolite in humans Clin Chem 50 2004 936 937
76. N. Stephanson, A. Helander, and O. Beck Alcohol biomarker analysis: simultaneous determination of 5-hydroxytryptophol glucuronide and 5-hydroxyindoleacetic acid by direct injection of urine using ultra-performance liquid chromatography-tandem mass spectrometry J Mass Spectrom 42 2007 940 949
77. K. Schulze, C. Gasch, K. Staufer, B. Nashan, A.W. Lohse, and K. Pantel Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma Int J Cancer 133 2013 2165 2171
78. Y.M. Li, S.C. Xu, J. Li, K.Q. Han, H.F. Pi, and L. Zheng Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease Cell Death Dis 4 2013 e831
79. S. Liu, N. Li, X. Yu, X. Xiao, K. Cheng, and J. Hu Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells Gastroenterology 144 2013 1031 1041 [e1010]
80. A. Satelli, Z. Brownlee, A. Mitra, Q.H. Meng, and S. Li Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface Vimentin-based methods for monitoring breast cancer therapeutic response Clin Chem 61 1 2014 259 266
81. S.X. Han, J.I. Wang, X.J. Guo, C.C. He, X. Ying, and J.L. Ma Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma J Immunol Res 2014
82. M. Capurro, I.R. Wanless, M. Sherman, G. Deboer, W. Shi, and E. Miyoshi Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89 97
83. Q. Shen, J. Fan, X.R. Yang, Y. Tan, W. Zhao, and Y. Xu Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study Lancet Oncol 13 2012 817 826
84. J.L. Zhang, Y.B. Qian, L.X. Zhu, and Q.R. Xiong Talin1, a valuable marker for diagnosis and prognostic assessment of human hepatocelluar carcinomas Asian Pac J Cancer Prev 12 2011 3265 3269
85. S. Ura, M. Honda, T. Yamashita, T. Ueda, H. Takatori, and R. Nishino Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma Hepatology 49 2009 1098 1112
86. S. Bala, Y. Tilahun, O. Taha, H. Alao, K. Kodys, and D. Catalano Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection J Transl Med 10 2012 151
87. S. Cermelli, A. Ruggieri, J.A. Marrero, G.N. Ioannou, and L. Beretta Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease PLoS One 6 2011 e23937
88. X.W. Wang, N.H. Heegaard, and H. Orum MicroRNAs in liver disease Gastroenterology 142 2012 1431 1443
89. M. Kornek, Y. Popov, T.A. Libermann, N.H. Afdhal, and D. Schuppan Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells Hepatology 53 2011 230 242
90. M. Kornek, M. Lynch, S.H. Mehta, M. Lai, M. Exley, and N.H. Afdhal Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis Gastroenterology 143 2012 448 458
91. M. Kornek, and D. Schuppan Microparticles: modulators and biomarkers of liver disease J Hepatol 57 2012 1144 1146
92. R.T. Stravitz, R. Bowling, R.L. Bradford, N.S. Key, S. Glover, and L.R. Thacker Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure Hepatology 58 2013 304 313
93. C. Wu, F. Li, G. Niu, and X. Chen PET imaging of inflammation biomarkers Theranostics 3 2013 448 466
94. H. Ittrich, K. Peldschus, N. Raabe, M. Kaul, and G. Adam Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy Rofo 185 2013 1149 1166
95. C. Sclavons, C. Burtea, S. Boutry, S. Laurent, L. Vander Elst, and R.N. Muller Phage display screening for tumor necrosis factor-alpha-binding peptides: detection of inflammation in a mouse model of hepatitis Int J Pept 2013 2013 348409
96. D.C. Rockey Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography Gastroenterology 134 2008 8 14
97. P.C. Georges, J.J. Hui, Z. Gombos, M.E. McCormick, A.Y. Wang, and M. Uemura Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis Am J Physiol Gastrointest Liver Physiol 293 2007 G1147 G1154
98. J.A. Talwalkar Elastography for detecting hepatic fibrosis: options and considerations Gastroenterology 135 2008 299 302
99. Y.E. Chon, E.H. Choi, K.J. Song, J.Y. Park, Y. Kim do, and K.H. Han Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis PLoS One 7 2012 e44930
100. A. Sagir, A. Erhardt, M. Schmitt, and D. Haussinger Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage Hepatology 47 2008 592 595
101. V. de Ledinghen, J. Vergniol, M. Capdepont, F. Chermak, J.B. Hiriart, and C. Cassinotto Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations J Hepatol 60 2014 1026 1031
102. M. Sasso, M. Beaugrand, V. de Ledinghen, C. Douvin, P. Marcellin, and R. Poupon Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes Ultrasound Med Biol 36 2010 1825 1835
103. Y.E. Chon, K.S. Jung, S.U. Kim, J.Y. Park, Y.N. Park, and Y. Kim do Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population Liver Int 34 2014 102 109
104. R. Lencioni Evolving strategies in the diagnosis of hepatocellular carcinoma J Hepatol 54 2011 184 186
105. K.E. Bremner, A.M. Bayoumi, M. Sherman, and M.D. Krahn Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis Can J Gastroenterol 21 2007 491 500
106. A. Sangiovanni, M.A. Manini, M. Iavarone, R. Romeo, L.V. Forzenigo, and M. Fraquelli The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis Gut 59 2010 638 644
107. K. Khalili, T.K. Kim, H.J. Jang, L.K. Yazdi, M. Guindi, and M. Sherman Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology 54 2011 2048 2054
108. D.Z. Xu, X.Y. Wang, X.L. Shen, G.Z. Gong, H. Ren, and L.M. Guo Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings J Hepatol 59 2013 450 456
109. C.L. Lai, S.H. Ahn, K.S. Lee, S.H. Um, M. Cho, and S.K. Yoon Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B Gut 63 6 2013 996 1004
110. A.A. Betancourt, C.A. Delgado, Z.C. Estevez, J.C. Martinez, G.V. Rios, and S.R. Aureoles-Rosello Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens Int J Infect Dis 11 2007 394 401
111. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
112. X. Forns, E. Lawitz, S. Zeuzem, E. Gane, J.P. Bronowicki, and P. Andreone Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 7 2014 1669 1679
113. A.M. Di Bisceglie, E. Janczweska-Kazek, F. Habersetzer, W. Mazur, C. Stanciu, and V. Carreno Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection Gastroenterology 147 1 2014 119 131
114. Arun J. Sanyal, M. Sunder, Robert Henry, Hanns-Ulrich Marschall, Linda Morrow, and Cathi I. Sciacca A new therapy for nonalcoholic fatty liver disease and diabetes? INT747 - the first FXR hepatic therapeutic study AASLD 50 S4 2009 A183
115. S.A. Polyzos, J. Kountouras, E. Zafeiriadou, K. Patsiaoura, E. Katsiki, and G. Deretzi Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease J Renin Angiotensin Aldosterone Syst 12 2011 498 503
116. M.D. Beaton, S. Chakrabarti, M. Levstik, M. Speechley, P. Marotta, and P. Adams Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease Aliment Pharmacol Ther 37 2013 720 729
117. S. Mudaliar, R.R. Henry, A.J. Sanyal, L. Morrow, H.U. Marschall, and M. Kipnes Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 145 2013 574 582 [e571]
118. Y. Takeshita, T. Takamura, M. Honda, Y. Kita, Y. Zen, and K.I. Kato The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial Diabetologia 57 5 2014 878 890
119. R. Dohil, S. Schmeltzer, B.L. Cabrera, T. Wang, J. Durelle, and K.B. Duke Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease Aliment Pharmacol Ther 33 2011 1036 1044
120. E. Boettcher, G. Csako, F. Pucino, R. Wesley, and R. Loomba Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther 35 2012 66 75
121. M.J. Armstrong, D. Barton, P. Gaunt, D. Hull, K. Guo, and D. Stocken Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial BMJ Open 3 2013 e003995
122. E. Nguyen-Khac, T. Thevenot, M.A. Piquet, S. Benferhat, O. Goria, and D. Chatelain Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis N Engl J Med 365 2011 1781 1789
123. B.C.Y.Z. Ann Sing Lee, Foon Yiu Cheung, Philip Kwong, Ashley Chi Kin Cheng, Maria Lai, and Chloe Kwok Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) Asco Annual Meeting 2012
124. A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, and J.L. Van Laethem Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63
125. N. Naqi, S. Ahmad, S. Murad, and J. Khattak Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label phase II feasibility study Hematol Oncol Stem Cell Ther 7 2014 27 31
126. C.H. Hsu, Y.C. Shen, Z.Z. Lin, P.J. Chen, Y.Y. Shao, and Y.H. Ding Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma J Hepatol 53 2010 126 131
127. M.H. Bang, T. Van Riep, N.T. Thinh, H. Song le, T.T. Dung, and L. Van Truong Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial Anticancer Res 30 2010 5145 5151
128. E.S. Glazer, M. Piccirillo, V. Albino, R. Di Giacomo, R. Palaia, and A.A. Mastro Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma J Clin Oncol 28 2010 2220 2226
129. Austin G. Duffy OER, Susanna Varkey Ulahannan, Suzanne Fioravanti, Aradhana Venkatesan, Ismail B. Turkbey, and Peter L. Choyke A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib Asco Annual Meeting 2013
130. S. Qin YB, S. Ye, J. Fan, H. Lim, J.Y. Cho, and S. Thongprasert Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients Asco Annual Meeting 2010
131. F. Ji, B. Yang, X. Peng, H. Ding, H. You, and P. Tien Circulating microRNAs in hepatitis B virus-infected patients J Viral Hepat 18 2011 e242 e251
132. Y. Chen, J. Chen, H. Wang, J. Shi, K. Wu, and S. Liu HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1 PLoS Pathog 9 2013 e1003248
133. J. Xu, C. Wu, X. Che, L. Wang, D. Yu, and T. Zhang Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis Mol Carcinog 50 2011 136 142
134. Y. Dang, D. Luo, M. Rong, and G. Chen Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET PLoS One 8 2013 e61054
135. V. Rottiers, and A.M. Naar MicroRNAs in metabolism and metabolic disorders Nat Rev Mol Cell Biol 13 2012 239 250
136. H. Su, J.R. Yang, T. Xu, J. Huang, L. Xu, and Y. Yuan MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity Cancer Res 69 2009 1135 1142
137. S. Bala, J. Petrasek, S. Mundkur, D. Catalano, I. Levin, and J. Ward Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases Hepatology 56 2012 1946 1957
138. J. Wen, and J.R. Friedman miR-122 regulates hepatic lipid metabolism and tumor suppression J Clin Invest 122 2012 2773 2776
139. L. Liang, C.M. Wong, Q. Ying, D.N. Fan, S. Huang, and J. Ding MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2 Hepatology 52 2010 1731 1740
140. G. Szabo, and S. Bala MicroRNAs in liver disease Nat Rev Gastroenterol Hepatol 10 2013 542 552
141. S. Bala, and G. Szabo MicroRNA signature in alcoholic liver disease Int J Hepatol 2012 2012 498232
142. B. Wang, S. Majumder, G. Nuovo, H. Kutay, S. Volinia, and T. Patel Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice Hepatology 50 2009 1152 1161
143. Y. Zhang, W. Wei, N. Cheng, K. Wang, B. Li, and X. Jiang Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling Hepatology 56 2012 1631 1640
144. G. Cai, and Y. Liu Diagnosing advanced versus early-stage hepatocellular carcinoma J Clin Oncol 30 2012 2167 [author reply 2168]
145. A.J. van der Meer, W.R. Farid, M.J. Sonneveld, P.E. de Ruiter, A. Boonstra, and A.J. van Vuuren Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122 J Viral Hepat 20 2013 158 166
146. A. Budhu, H.L. Jia, M. Forgues, C.G. Liu, D. Goldstein, and A. Lam Identification of metastasis-related microRNAs in hepatocellular carcinoma Hepatology 47 2008 897 907
147. T.W. Hoffmann, G. Duverlie, and A. Bengrine MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy Virol J 9 2012 109
148. Y. Murakami, T. Yasuda, K. Saigo, T. Urashima, H. Toyoda, and T. Okanoue Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues Oncogene 25 2006 2537 2545
149. S. Bala, M. Marcos, and G. Szabo Emerging role of microRNAs in liver diseases World J Gastroenterol 15 2009 5633 5640